Bozdoğan Onder, Atasoy Pinar, Erekul Selim, Bozdoğan Nazan, Bayram Merih
Kirikkale University Faculty of Medicine, Kirikkale State Hospital, Turkey.
Int J Gynecol Pathol. 2002 Oct;21(4):375-82. doi: 10.1097/00004347-200210000-00007.
The purpose of this study was to evaluate the distribution and frequency of apoptosis-related proteins and their correlation with estrogen, progesterone, and androgen receptors in endometrial tissues. Immunohistochemical analyses of bcl-2, bax, bcl-x, and steroid receptors were performed in 22 endometrial carcinomas, 26 endometrial hyperplasias, and 19 cases of normal cyclical endometrium. Bcl-2 was expressed in 45.4% of carcinomas and 92.3% of hyperplasias. Bax immunostaining was found in 90.9% of carcinomas and 76.9% of hyperplasias. Bcl-x positivity was similar in carcinomas (68.1%) and endometrial hyperplasias (76.9%). In normal cyclical endometria, bcl-2 staining was intense and diffuse in the proliferative phase, but decreased dramatically in the early and mid-secretory phase to reappear in the late secretory phase. Bax was expressed throughout the menstrual cycle but more strongly in the secretory phase. Bcl-x displayed a similar degree of expression in proliferative and secretory endometria. Nineteen carcinomas (86.3%), 25 hyperplasias (96.1%), and 18 normal cyclical endometria (94.7%) were positive for estrogen receptor (ER). Progesterone receptor (PR) was observed in 20 carcinomas (90.9%), all hyperplasias (100%), and 18 normal cyclical endometria (94.7%). Androgen receptor (AR) positivity was seen in 7 carcinomas (31.8%), 6 hyperplasias (23.0%), and 3 normal cyclical endometria (15.7%). There was a statistically positive correlation between bcl-x and ER and a tendency toward significant correlation between bcl-x and PR and between ER and PR in carcinomas. In hyperplasias, there was a significant positive correlation between bcl-2 and PR and between bcl-2 and bax and a negative correlation between ER and bax. There was a statistically significant difference for bcl-2 (p = 0.001) and bax (p = 0.001) between the hyperplasia and carcinoma groups. There was increased expression of bax, decreased expression of bcl-2, and persistence of bcl-x protein in advanced endometrial carcinomas. Our findings show that ovarian hormones have a regulatory role on bcl-2 protein and that there is a correlation between other members of the bcl-2 family (bcl-x and bax) and steroid hormone receptors. Bax/bcl-x may be the major control mechanisms of apoptosis in advanced carcinomas; other members of the bcl-2 family may also be under hormonal control.
本研究的目的是评估凋亡相关蛋白在子宫内膜组织中的分布及频率,以及它们与雌激素、孕激素和雄激素受体的相关性。对22例子宫内膜癌、26例子宫内膜增生和19例正常周期性子宫内膜进行了bcl-2、bax、bcl-x和类固醇受体的免疫组织化学分析。bcl-2在45.4%的癌组织和92.3%的增生组织中表达。bax免疫染色在90.9%的癌组织和76.9%的增生组织中可见。bcl-x在癌组织(68.1%)和子宫内膜增生组织(76.9%)中的阳性率相似。在正常周期性子宫内膜中,bcl-2染色在增殖期强烈且弥漫,但在分泌早期和中期显著减少,在分泌晚期重新出现。bax在整个月经周期均有表达,但在分泌期表达更强。bcl-x在增殖期和分泌期子宫内膜中的表达程度相似。19例癌组织(86.3%)、25例增生组织(96.1%)和18例正常周期性子宫内膜(94.7%)雌激素受体(ER)呈阳性。20例癌组织(90.9%)、所有增生组织(100%)和18例正常周期性子宫内膜(94.7%)观察到孕激素受体(PR)。7例癌组织(31.8%)、6例增生组织(23.0%)和3例正常周期性子宫内膜(15.7%)雄激素受体(AR)呈阳性。在癌组织中,bcl-x与ER之间存在统计学上的正相关,bcl-x与PR之间以及ER与PR之间有显著相关的趋势。在增生组织中,bcl-2与PR之间、bcl-2与bax之间存在显著正相关,ER与bax之间存在负相关。增生组与癌组之间bcl-2(p = 0.001)和bax(p = 0.001)存在统计学显著差异。在晚期子宫内膜癌中,bax表达增加,bcl-2表达减少,bcl-x蛋白持续存在。我们的研究结果表明,卵巢激素对bcl-2蛋白具有调节作用,并且bcl-2家族的其他成员(bcl-x和bax)与类固醇激素受体之间存在相关性。Bax/bcl-x可能是晚期癌中凋亡的主要控制机制;bcl-2家族的其他成员也可能受激素控制。